AMGN Ticker Curator

• Barclays initiates Equal Weight at $185 PT, notes Phase 3 MARITIME readout as key debate but offset by strong guidance
• Wells Fargo raises PT to...

Neutral Form 144 notice for planned sale of 54,792 AMGN shares from equity grants.

• Sources: 24,291 shares (05/01/2017 grant) + 30,501 shares...

Key pipeline refinement for Repatha's (evolocumab) future:

• Phase 1 trial compares bioavailability of two subcutaneous formulations in healthy...

GLP-1 demand explosion spotlights private ecosystem players for scaling:

• CDMOs like Corden Pharma, Axplora driving production.
• Sterile fill-finish...

Accumulating bullish signals fuel AMGN's trend amid all-time highs:

• Zacks Momentum Score A: Shares up 10.6% in 4 weeks; 9 analysts lifted FY2026...

Institutional shift: DNB Asset Management AS reduced its AMGN stake by 10.4%, selling 16,121 shares to hold 139,527 shares worth ~$39.38M.

• Mixed...

Institutional Moves

• 🔥 Boston Trust Walden Buy: Boston Trust Walden Corp raised its stake in Amgen by 390.15%, purchasing 57,235 shares to own...

Fresh institutional interest in AMGN near highs:

• Boston Trust Walden raised stake 390%, adding 57,235 shares to own 71,905 worth $23.5M.
• Others...

• Kingswood Wealth Advisors raised its AMGN stake by 26.25%, adding 1,027 shares to hold 4,939 worth $1.62M
• Joins others boosting holdings: Leo...

Stock momentum surges, but analysts stay cautious:

• Hit all-time high $385.63 and new 52-week high
• Equal weight at $350; Leerink raises to $355
• Freedom downgrades to Hold at $375, notes strong momentum
  Watch if price pulls back toward targets.

Contrarian signal from a top holder: Primecap sold 924,100 AMGN shares in Q3, down 8.7% to 9.7M shares (2.1% of portfolio).

• Stock at $384 open,...

Quick Recap

• Amgen announced presentations at the 46th Annual TD Cowen Health Care Conference and Citi's 2026 Virtual Oncology Leadership...

Short-term timeline highlights volatility:

• 2/25 Close (4 PM ET): $384.33 +1.46 (+0.38%)
• Premarket (4:53 AM ET 2/26): $382.62 -1.71 (-0.44%), vol 50
• Extended (5:05 AM ET): $383.71 -0.62 (-0.16%)

Watch for open amid downward premarket shift.

AMGN outperforms Dow across periods, fueled by $206.4B market cap and biotech portfolio:

• 3-months: +14.5% vs. Dow +5.9%
• 52-weeks: +23.6% vs. +13.2%
• YTD: +17% vs. +2.3%
  Bullish trend persists post-Q4 beat ($9.9B rev) and solid 2026 guidance.

• Shares up 14.5% in past 3 months on strong momentum
• Impressive Q4 2025 results reported, with webcast announced
• Presenting at 46th TD Cowen Healthcare Conference
• Analysts mixed on valuation and growth prospects